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Abstract Mistletoes are a group of obligate plant semi-
parasites in the order Santalales. These clumps of plants
growing on a wide range of host plants have been tradi-
tionally regarded as medicinal repositories. However, cur-
rent scientific discoveries have validated their health
potentials like never before. Their extracts containing
alkaloids, viscotoxins, lectins, and polysaccharides have
been evidenced to possess a myriad biological potentials
including cancer inhibition. Mistletoes have emerged as
promising alternative therapy against colon, oral, lung, and
pancreas cancers. The plant extracts bolster immunity,
delay tumour initiation and progression, kill malignant
tumours, stabilize DNA, alleviate side effects of chemo-
therapeutics, improve the lifespan, and coping ability of
cancer patients and survivors. A range of proprietary for-
mulations viz. Iscador, Eurixor, Helixor, Lektinol, Isorel,
Iscucin, Abnoba-viscum and recombinant lectin ML-1 are
already being commercialized. This review presents an
informative account on the recent developments in mistle-
toe-mediated cancer management. The underlying mecha-
nisms, possibilities and limitations in cancer therapeutic
development are outlined for kindling both researcher and
public interest.
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Introduction
Mistletoes are semi-parasitic plants belonging to family
Misodendraceae, Loranthaceae, Santalaceae, Viscaceae,
etc. grouped under the order Santalales. Though, there
exist more than 100 species, the most recognized genera
are Viscum, Phoradendron, Arceuthobium, Peraxilla,
Loranthus, Amylotheca, Amyema, Taxillus, Psittacanthus,
Scurrula, etc. The list of mistletoes with documented
medicinal roles has been given in Table 1. They are dis-
tributed across Europe, America, Asia and Africa to Aus-
tralia and New Zealand. Depending on their geographical
location, the mistletoes are named European, American,
Mexican, Korean, African, Japanese, and Indian, etc. It is
the state floral emblem of Oklahoma state in the USA.
Mistletoes have tiny, oval green leaves on forked branches
(Fig. 1). These plants bear flowers that develop into white
or red berries. The chlorophylls enable them to carry out
photosynthesis, but the nutritional requirement is not sat-
isfied by this meagre carbohydrate produced. So, these
plants penetrate their haustoria into the host plants and
siphon off the nutrients. They parasitize a wide range of
trees, namely, apple, almond, plum, eucalyptus, beech,
poplar, spruce, rosewood, maple, sweetgum, oak, mesquite,
willow, elm, pine, juniper, etc. These plants have a rich
traditional significance. Sprigs of mistletoe are hung as
Christmas decorations, as the bouquets are believed to
be the harbingers of good luck. In folklore medication,
mistletoes have been prolifically used. Several Native
American tribes used juniper mistletoe as medication, tea
and food. Xhosa people of South Africa used it for ame-
lioration of sore throat and lumbago. The Japanese used it
against hypertension and rheumatism. Mistletoes are
claimed to exert antioxidant, analgesic, anti-inflamma-
tion, immune-stimulatory, antiglycemic, neuroprotective,
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and antihypertensive properties. Further, the ability to
provide relief from diarrhoea, cardiovascular risk, osteo-
arthritis, osteoporosis, and epilepsy has been documented.
Now, results of randomised clinical trials are surfacing,
lending credentials to the ethnic uses.
Recently, their intervention in carcinogenesis has grab-
bed the interest of the researchers. So far, inhibition against
breast, lung, pancreas, gastric cancer, and melanoma has
been reported. This review aims to present the major
findings in the anti-proliferative properties of mistletoes for
integration of these plants in mainstream onco-care prac-
tices. The bioactive phytochemicals and the mechanisms
involved have been outlined.
Phytochemical profile
A wide repertoire of phytochemicals has been extracted
using various solvents and analyzed by chromatographic
techniques. Lectins that bind specifically to the carbohy-
drate moiety of glyco-conjugates are abundant in the mis-
tletoes. Xiao et al. (2010) extracted polysaccharides
possible antitumor potential from Scurrula parasitica.
Herbal tea concocted from mistletoe has the triterpenoids,
oleanolic acid and betulinic acid in high concentrations
(Jager et al. 2011). Moustapha et al. (2011) identified gallic
acid, two flavonol-3-biosides and the non-protein amino
acid N-methyl-trans-4-hydroxy-L-proline from Psittacan-
thus calyculatus, a mistletoe species abundant in Mexico.
Yang et al. (2011) isolated and identified triterpenoids and
triterpenoid saponins of V. liquidambaricolum that exhib-
ited cytotoxic activities against four human tumour cell
lines (HeLa, SGC-7901, MCF-7, and U251). The acetone
extract of P. brachystachyum yielded morolic acid as the
major component. Also, b-sitosterol, stigmasterol, tria-
contanol, squalene, a- and b-amyrin, lupeol, lupenone, a
range of aldehydes and phenolic acids were identified from
the extracts (Lopez-Martinez et al. 2013). Omeje et al.
Table 1 The common and
scientific names of referred
mistletoes and the families to
which they belong










Viscaceae Alonso-Castro et al. (2012)








Loranthaceae Cebovic et al. (2008)
Hong and Lyu (2012)
Yang et al. (2011)
Catkin Taxillus sutchuenensis
Taxillus liquidambaricola
Loranthaceae Liu et al. (2012)
Mexican Psittacanthus calyculatus Loranthaceae Moustapha et al. (2011)
Loranthus Scurrula parasitica L. Loranthaceae Xiao et al. (2010)
Fig. 1 a Mistletoe plant on host tree, b mistletoe with berries
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(2012) isolated lupeol-based triterpenoid esters from the
leaves of L. micranthus Linn. Zhao et al. (2012) determined
the cytotoxic activities of V. coloratum flavonoid com-
pounds pachypodol and ombuine against four human
tumour cell lines (HeLa, SGC-7901, MCF-7, and U251)
and obtained promising results. Liu et al. (2012) evaluated
the anti-proliferative activities of the aqueous-ethanol
extract of Taxillus sutchuenensis on A549 cells. The ethyl-
acetate fractions had the highest anti-proliferative activity
which is attributed to the phenolic compounds. The major
anticancer compounds have been presented in Fig. 2.
Validated anticancer properties
Many types of mistletoes have demonstrated enhanced
cancer surveillance, antitumor, anti-angiogenic, and apop-
totic activities. Distinct inhibitory effects have been
observed against colon, oral, lung, pancreas cancers. Sev-
eral commercial preparations are administered as part of
complementary onco-therapy. Peritumoral injections are
the most common method of mistletoe extract administra-
tion. V. album is by far the most-studied and promising
mistletoe. Several literature reviews have documented the
developments from time to time. Laszczyk (2009) reviewed
the triterpene-rich mistletoe shoots as possible cancer
therapy. Ostermann et al. (2009) reviewed the piling evi-
dences and reported the correlation between Iscador usage
and survivability. Melzer et al. (2009) formulated a review
on the quality of life improvement by mistletoe prepara-
tions. Distillation of the conclusions from control trials and
questionnaires revealed the efficacy in suppressing solid
tumours. Kienle and Kiene (2010) scoured the databases for
deriving the impact of V. album on the quality of life of
cancer patients. Both randomized and non-randomized
control trials were assessed. Studies with methodological
precision showed better coping, fatigue, sleep, exhaustion,
energy, nausea, vomiting, appetite, depression, anxiety,
ability to work and emotional and functional well-being.
Further, it was well tolerated and found to alleviate the side
effects of chemotherapy and radiation.
Zwierzina et al. (2011) have reviewed the anti-prolifer-
ative role of recombinant lectin aviscumine. Fu et al. (2011)
attributed the anticancer property of mistletoe lectins to the
modulation of the programmed cell death pathways. Olaku
and White (2011) reviewed the clinical trials in cancer
populations. Metelmann et al. (2012) reviewed the impact
of mistletoe extract in direct contact with the tumour tissue
and held activation of macrophage polarization followed by
induced cytotoxicity as the inhibitory pathway.
Commercial anticancer preparations
The National Center for Complementary and Alternative
Medicine under the aegis of National Cancer Institute
constantly searches for new, effective anticancer drugs. Till
now an array of mistletoe extracts have been formulated as
drugs, namely Iscador, Eurixor, Helixor, Lektinol, Isorel,
Iscucin, Abnoba-viscum and recombinant lectin ML-1. The
extracts are applied as injection into skin, vein, pleural
cavity or tumour. Friedel et al. (2009) evaluated the effi-
cacy of treatment with mistletoe extract Iscador in non-
metastatic colorectal carcinoma patients through a cohort
study. These results suggest the beneficial effect of Iscador
therapy. Iscador was well tolerated without life-threatening
adverse reactions, drug interactions, or tumour enhance-
ment. Gren (2009) also studied the influence of Iscador Qu,
M and P (5 mg/kg) on the total protein concentration in
blood serum and proportions of blood protein fractions.
A significant increase in albumin fraction level and lym-
phocyte count was observed that was assumed to be reason
of enhanced immunity.
Research findings
This review strives to furnish the key developments in the
current times. Monira et al. (2009) examined the effect of
lectin from V. album subsp. coloratum on cytokine gene
expression in human colon adenocarcinoma Caco-2 cells
and in the mouse intestine. The results indicated the up-
regulation of the gene expression of the proinflammatory
cytokines interleukin (IL)-8, tumor necrosis factor-alpha
(TNF-a) and IL-6 in Caco-2 cells and TNF-a and IL-6 in
the duodenum. (Kirsch and Hajto 2011) studied the effect
Fig. 2 Key anticancer
compounds found in mistletoe
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of lectins on sarcoma patients. When the optimal dose of
0.75–1.0 ng/kg lectin was given twice a week subcutane-
ously, remissions of tumor symptoms were conspicuous.
Lectins functioning as ligands for pattern recognition
receptors of the natural immune systems are docked to
ganglioside molecules (CD75) of monocytes and granulo-
cytes, stimulating the natural antitumor mechanisms. Ka-
meda et al. (2011) observed the effect of 30 months of
mistletoe therapy on a patient diagnosed with nodal large
cell ALK-1-anaplastic lymphoma compounded with lym-
phomatoid papulosis. After the designated period, com-
plete remission of the tumor was seen. Park et al. (2012)
investigated the effect of Abnobaviscum F formulated
from V. album extract on the growth and survival of dif-
ferent leukaemia cell lines. The treatment reduced survival
and induced apoptosis of human myeloid leukaemia K562,
human plasmacytoma RPMI-8226 and murine lymphocytic
leukaemia L1210 cells in culture. The apoptosis mecha-
nism was intrinsic, associated with the activation of cas-
pase-9, JNK-1/2 and p38 MAPK, as well as with the down-
regulation of Mcl-1, and inhibition of ERK-1/2 and PKB
phosphorylation.
Antimutagenic
Safeguarding against mutagens is of major importance in
cancer prevention at which mistletoe extracts have been
fairly effective. Burkhart et al. (2010) carried out an
investigation on the protective effect of mistletoe extract on
human peripheral blood mononuclear cells of healthy
blood donors and the T cell leukaemia Jurkat cell line
against the alkylating agent 4-hydroperoxycyclopho-
sphamide. The cells being incubated with the extract for
60–65 h were exposed to the alkylating agent for 2 h. The
extract exerted protection towards only healthy cells and
not towards the Jurkat cells. The biological action was
evident from the enhanced mitochondrial activity and
replication of the healthy cells. Hong and Lyu (2012)
investigated the antimutagenic potential of V. album L. var.
coloratum agglutinin. The Salmonella typhimurium strain
TA98 was subjected to the mutagens 2-aminoanthracene
and furylfuramide; whereas Salmonella typhimurium strain
TA100 was subjected to sodium azide and 2-aminoan-
thracene. The protective ability varied from moderate to
negligible. Sekeroglu and Sekeroglu (2012) investigated
the cyto-genotoxicity lowering effects of pre-treatment
with V. album extract on methotrexate-induced chromo-
somal aberrations in mouse bone-marrow cells. Pre-treat-
ment of mice by gavaging with the extract at the dose
250 mg/kg/day for 10 days caused a significant decrease in
chromosomal aberrations and in the number of aberrant
cells with the mutations.
Anti-angiogenesis, antiproliferation, and apoptosis
Angiogenesis, proliferation, and apoptosis are interlinked
processes during carcinogenesis. Once mutation occurred
and tumour was initiated, delaying its spread is the next
challenge to tackle. Ma et al. (2008) investigated the effect
of Chinese mistletoe lectin (CML-55) on colon cancer cell
line CT26-bearing BALB/c mice. Results showed that
compared to PBS treated mice, CML-55 treated group
showed significantly delayed colon cancer progression.
Enhancement in the tumour antigen-specific activation and
proliferation of CD4? and CD8? T cells was observed.
Also, increase in the NK cell numbers was seen. Promotion
of both innate and adaptive immunity projects the extract
as an anticancer candidate. Role of mistletoe at this phase
have been investigated with appreciable results. The EA
hy926 cell line is a continuous human cell line that displays
a number of features characteristic of vascular endothelial
cell. When plated on a matrigel, they undergo a process of
morphological re-organization mimicking angiogenesis.
Elluru et al. (2009) determined the cytotoxicity of V. album
extract on matrigel-treated EA-hy926 cells both in vitro
and in vivo. The extract caused significant inhibition of
angiogenesis by bringing many changes in vessel forma-
tion. Choi et al. (2012) analyzed the proliferation sup-
pressive effect V. album subsp. coloratum lectin on
HepG2Acells. A dose as low as 1–5 pg/ml dose could exert
cancer cell-specific toxicity. Alonso-Castro et al. (2012)
evaluated cytotoxicity of ethanolic extracts of P. serotinum
injected intraperitoneally into C57BL/6 mice implanted
with TC-1 cells for 25 consecutive days. The extract at the
dose 10 mg/kg inhibited the tumour growth by 69 %,
increasing the release of IL-2, IL-6, and IFN-c. Podlech
et al. (2012) showed that Iscador Q reduced the migratory
and invasive potential of glioblastoma cells. It delayed
tumor growth by NK-cell-mediated glioblastoma cell lysis.
Cyclodextrin solubilized triterpene acid- or lectin-con-
taining extracts of mistletoe inhibited cell proliferation and
demonstrated cytotoxic properties on acute lymphoblastic
leukaemia NALM-6 cells in vitro. Furthermore, caspase
activity demonstrated that these extracts were able to
induce apoptosis in the cancer cells through both caspase-8
and -9 dependent pathways. The treatment of mice with the
extract prolonged mean survival to 50.5 days compared to
39.3 days in the phosphate-buffered saline group (Dele-
binski et al. 2012).
Post-surgery supportive care
Mistletoe extracts have been found to confer amelioration
to post-surgery cancer patients. Fatigue decrease and
overall quality of life improvement are the benefits
16 3 Biotech (2014) 4:13–20
123
imparted. Elsasser-Beile et al. (2005) observed the effect
of intravesical administration of mistletoe lectin to post-
surgery superficial urothelial bladder carcinomas patients.
After transurethral resection, each patient received mistle-
toe extracts with lectin concentrations between 10–5,000
ng/ml. The injected extract was retained in the bladder for
2 h. Within the observation time of 12 months, 70 %
patients remained tumour-free. The lectin-rich extract
might be a suitable alternative to the prevalent BCG ther-
apy, without the side-effects associated with the latter.
Wode et al. (2009) investigated the impact of mistletoe
extracts on cancer-related fatigue. A patient with recurrent
breast cancer history of 10 years was given this plant
extract. A two and half year continuation of the drug
exerted a dose-dependent benefit in decreasing fatigue.
Matthes et al. (2010) conducted a multicenter, controlled
observational study to determine the adjuvant chemother-
apy with gemcitabine supported by Iscador in the pancre-
atic carcinoma patients after surgery. With symptom
control, overall rise in survival was observed. Eisenbraun
et al. (2011) evaluated the effect of aqueous mistletoe
extracts on health-related quality of life of breast cancer
patients on chemotherapeutics. Questionnaires pertaining
the therapeutic value of the extract abnobaVISCUM()
Mali were administered to the patients. Self-assessment
was analyzed at four different phases of the regimen.
Tolerability was recorded very well for 91 % of the
patients and the efficacy was rated as good or very good for
94 %. 89 % of the patients reported about a good or very
good benefit. Brandenberger et al. (2012) administered a
questionnaire to cancer patients suffering from different
types of cancers at the beginning and after 3 months
of mistletoe administration. Analysis of the interview
revealed higher vitality and autonomy, better ability to
cope with the cancer in the patients undergoing mistletoe
therapy. Bu¨ssing et al. (2012) employed a random-effect
meta-analysis to find out the effect of Iscador and observed
short-time beneficial psychosomatic effect. Kim et al.
(2012) evaluated safety and efficacy of a standardized
mistletoe extract abnobaVISCUM() in operated patients
with gastric cancer. The effect of oral therapy with doxif-
luridine combined with subcutaneous injection of mistletoe
extract three times per week from postoperative day 7 to
week 24 in increasing doses was monitored. Health status,
leukocyte and eosinophil counts increased significantly and
diarrhoea incidences were low.
Drug side-effect amelioration
Troger et al. (2009) carried out a prospective randomized
study to determine the immunostimulant property of Isc-
ador M in breast cancer patients. Conventional cancer
drugs viz. cyclophosphamide, adriamycin and 5-fluoro-
uracil led to neutropenia (abnormal decrease in the number
of neutrophils). The chemotherapy-induced neutropenia
amelioration effect of the mistletoe-based drug was stud-
ied. The treated group showed an improvement in the
neutrophil counts. Bar-Sela et al. (2012) administered
chemotherapy plus Iscador to patients with non-small-cell
lung cancer. Though survival time was similar in both the
groups, the chemotherapy dose reductions, severe non-
haematological side-effects and hospitalizations were less
frequent in patients treated with Iscador.
Synergistic effects
Several instances of mistletoe potentiating chemical drugs
exist. Freudlsperger et al. (2010) investigated the syner-
gistic antiproliferative efficacy of mistletoe lectin-I and the
PPAR-c ligand rosiglitazone in malignant melanoma cells.
Results of the XTT cell proliferation assay showed that the
combined therapy is more effective than individual treat-
ment. Metastatic pancreatic is a fatal disease with brief
median survival time of 3–6 months only. Oxaliplatin and
gemcitabine are the standard chemotherapy to combat the
cancer. Ritter et al. (2010) investigated the adjunct therapy
possibilities with mistletoe extract. In a case study,
37 weeks after surgery, the patient demonstrated a sus-
tained partial remission, and the chemotherapy was stop-
ped. Contrary to normal trend, the patient showed no signs
of tumour progression, even 10 months later. The long-
term remission was attributed to the mistletoe therapy
initiated after the surgery. Micke et al. (2010) conducted a
questionnaire-based investigation on the usage of CAM in
lung cancer patients. 54 % of the patients reported using
CAM out of which 15 % used mistletoe. Iscador, the
aqueous preparation of V. album L. is regarded a potent
CAM. Sabova et al. (2010) investigated the cytotoxic and
apoptosis-inducing effects of aqueous mistletoe extract
alone or in combination with doxorubicin on Jurkat cells.
Dose-dependent DNA fragmentation was induced in Jurkat
cells individually as well as synergistically.
Mechanisms of action
Cebovic et al. (2008) employed supercritical CO2 extrac-
tion coupled with gas chromatography/mass spectrometry
for selective extraction and identification of therapeutic
compounds from V. album leaves. The extract exhibited
in vivo cytotoxicity towards Ehrlich carcinoma (EAC) cells
due to the induction of oxidative stress. Kovacs et al.
(2008) compared the effect of V. album extract and the
alkaloid vincristine on B cell lymphoma cell line WSU-1 in
3 Biotech (2014) 4:13–20 17
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an in vitro system. Both the substances first inhibited the
proliferation of the tumour cells which lead to apoptosis or
necrosis. Reduction in the DNA synthesis of the G2/M cell
cycle phase was decoded to the molecular pathway fol-
lowed. Both the substances led to dose-dependent apopto-
sis at 12 h as well as 24 h. Xiao et al. (2010) investigated
the antitumor activity of Scurrula parasitica leaf polysac-
charides. Intraperitoneal injection of the polysaccharide
inhibited S180 growth with a tumor inhibition rate of 54 %.
Analyses by immunohistochemistry techniques showed
that the polysaccharide down-regulates the expression of
Ki-67, CyclinD1, and Bcl-2 protein, and up-regulates the
expression of Bax protein. Li et al. (2011) investigated the
effect of CM-1, a lectin-I extracted from the Chinese
mistletoe on colorectal cancer cells. The in vitro and
in vivo effect on CLY and HT-29 cells were studied. Using
miRNA microarray assay and qRT-PCR analysis, the
anticancer action was decoded due to precursor degrada-
tion-mediated down-regulation of some miRNAs by CM-1.
The miR-135a and miR-135b were the miRNAs most
down-regulated. Stru¨h et al. (2012) solubilised the olean-
olic acid-rich triterpene extract from mistletoe by
2-hydroxypropyl-b-cyclodextrin on B16.F10 mouse mela-
noma cells. The solubilised extract showed high cytotox-
icity by causing DNA fragmentation, followed by loss of
membrane integrity and intracellular adenosine-50-triphos-
phate. Ucar et al. (2012) demonstrated that pretreatment
with the methanolic extract of V. album before heat shock
at 40 C increased apoptosis via caspase-3 activation
(60 %) in C6 glioma cells. This down-regulation of the
expression of Hsp27 and 14-3-3 chaperone proteins was
revealed to induce apoptosis. A schematic illustration of
the anticancer activity of lectin has been presented in
Fig. 3.
Side effects and future trends
FDA is yet to approve the mainstream use of mistletoe in
cancer therapy on the grounds of undesirable side-effects.
Some mistletoe extracts caused several types of human
cancer cells to grow faster. The major adverse effects
documented so far are inflammation, headaches, fever,
chills, and anaphylactic shocks.
Chemical makeup profiling is required. The nexus
between phytochemicals in the semi-parasite and the host
tree needs further verification. Efficacy of different species,
harvest time and fermentation period are the areas to be
addressed. Feeble water solubility of triterpenes hinders the
water extraction. Cyclodextrins have improved their solu-
bilizing property resulting in better biological activity.
Safety issues often blight the prospect of pharmaceutical
use of mistletoe extracts. Accidental ingestion has been
reported to cause gastric upset, seizure, eye irritation, etc.
Complaints of inflammation at the site of subcutaneous
injection have been recorded that must be verified. Huber
et al. (2011) conducted a 3-armed randomized, double-
blind clinical trial on healthy volunteers by giving them
subcutaneous injections of various doses of the drug
Iscucin Populi (IP) twice a week over a period of
12 weeks. Immunological assays showed eosinophilia and
an increase of CD4 cells but not an increase of the tumor
causing cytokine IL-6 negating doubts of safety. Still,
animal studies, and human trials are required to reach any
concrete conclusions. Heterogeneity of test animals often
gives rise to variation in results. So, collection of epide-
miological data is desired. The synergistic effect with other
anticancer agents needs to be explored. The dosage needs
to be standardized. The results pooled till now are not
consistent due to small sample size and methodological
heterogeneity. More accurate designs need to be planned
for reliable results.
Conclusions
The validated reports support the previous ethno-pharma-
cological relevance of mistletoes. The effective outcomes
ask for further assessment of the antiproliferative potential
of the extracts. Many species are threatened that must be
preserved. Side effects cause conflict in broader prescrip-
tion as adjunct therapy that must be addressed. Safety
parameters and proper dosage need to be ascertained.
Existing evidences may not be enough but given due
research impetus, a novel drug with comparable or superior
efficacy than paclitaxel, vincristine, epipodophyllotoxin,
and betulinic acid may emerge. Promotion of mistletoe as
complementary and alternative medicine (CAM) will cer-
tainly usher in a new hope for cancer therapy. It is certainly
Mistletoe leaves
Purification by affinity chromatography
Murine model
Extraction of lectin I
Cancer implantation
Intraperitoneal injection of lectin
Euthanizing the rat
Histological and immunological assay
Increment in the dendritic
cells and apoptosis induction 
Shrinkage of tumor
Fig. 3 Schematic diagram of mistletoe lectin-mediated anticancer
activity
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the time to view this poorly recognized botanical resource
in new light for which this review is expected to be a
catalyst.
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